Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. 2020 Jun 28;8(2):150-160. doi: 10.14218/JCTH.2020.00003. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke Journal of Hepatology Volume 67, … This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. Pegylated interferon-alfa treatment can also be considered in mild to moderate chronic hepatitis B patients. Copyright © 2017 European Association for the Study of the Liver. Chronic HBV infectio … EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. 2017 Mar;2(3):177-188. doi: 10.1016/S2468-1253(16)30189-3. Unable to load your delegates due to an error The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development.
Infection with hepatitis B virus (HBV) remains an important global public health problem with significant morbidity and mortality., , New information on the pathogenesis and management of HBV infection has become available since the previous EASL Clinical Practice Guidelines (CPGs) … All patients should be monitored for risk of disease progression and HCC. 2020 Jun 24;4(2):133-137. doi: 10.1002/ped4.12205. Epub 2020 May 25. Clipboard, Search History, and several other advanced features are temporarily unavailable. This especially applies to autochthonous hepatitis E virus (HEV) infection, which may be misdiagnosed as DILI and occurs more frequently in similar demographic groups.
doi: 10.1097/MD.0000000000021387.Pediatr Investig. Name must be less than 100 characters eCollection 2020 Jun.Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T.JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169. Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. Please enable it to take advantage of the complete set of features! Additional indications include the prevention of mother to child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy.
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, We use cookies to help provide and enhance our service and tailor content and ads. COVID-19 is an emerging, rapidly evolving situation. Epub 2017 Jan 20.Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD.World J Gastroenterol. Therefore, the EASL Guidelines for Hepatitis B presents updated recommendations for the optimal management of HBV infection. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The typical indication for treatment requires HBV DNA >2,000 IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration.